WO2005077983A3 - Modulating p38 kinase activity - Google Patents

Modulating p38 kinase activity Download PDF

Info

Publication number
WO2005077983A3
WO2005077983A3 PCT/US2005/003379 US2005003379W WO2005077983A3 WO 2005077983 A3 WO2005077983 A3 WO 2005077983A3 US 2005003379 W US2005003379 W US 2005003379W WO 2005077983 A3 WO2005077983 A3 WO 2005077983A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
kinase activity
tyrosine
phosphorylation
methods
Prior art date
Application number
PCT/US2005/003379
Other languages
French (fr)
Other versions
WO2005077983A2 (en
Inventor
Jonathan D Ashwell
Jesus Maria Salvador
Albert J Fornace
Paul R Mittelstadt
Original Assignee
Th And Human Services Esented
Jonathan D Ashwell
Jesus Maria Salvador
Albert J Fornace
Paul R Mittelstadt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Th And Human Services Esented, Jonathan D Ashwell, Jesus Maria Salvador, Albert J Fornace, Paul R Mittelstadt filed Critical Th And Human Services Esented
Publication of WO2005077983A2 publication Critical patent/WO2005077983A2/en
Publication of WO2005077983A3 publication Critical patent/WO2005077983A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the discovery that p38 protein kinase is uniquely phosphorylated at tyrosine 323 in certain cell types, for example, within T cells. Therefore, in one embodiment, invention provides compositions and methods for modulating p38 activity through phosphorylation of tyrosine 323. In other embodiments, the invention provides compositions and methods for modulating T cell activity by modulating phosphorylation of p38 at tyrosine 323.
PCT/US2005/003379 2004-02-05 2005-02-04 Modulating p38 kinase activity WO2005077983A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54199304P 2004-02-05 2004-02-05
US60/541,993 2004-02-05
US60243604P 2004-08-17 2004-08-17
US60/602,436 2004-08-17

Publications (2)

Publication Number Publication Date
WO2005077983A2 WO2005077983A2 (en) 2005-08-25
WO2005077983A3 true WO2005077983A3 (en) 2006-02-16

Family

ID=34864485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/003379 WO2005077983A2 (en) 2004-02-05 2005-02-04 Modulating p38 kinase activity

Country Status (1)

Country Link
WO (1) WO2005077983A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324083B1 (en) * 2007-10-22 2010-05-31 Consejo Superior De Investigaciones Cientificas PROCEDURE FOR THE DIAGNOSIS AND TREATMENT OF DISEASES THAT COURSE WITH ALTERATION OF KINASE P38, ELEMENTS NEEDED TO CARRY OUT IT AND ITS APPLICATIONS.
US9359418B2 (en) 2012-11-20 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use
CN113637078B (en) * 2021-07-16 2022-10-25 四川大学华西医院 Nano antibody, nucleic acid, expression vector, host cell aiming at protein kinase p38 delta and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038143A2 (en) * 2000-11-07 2002-05-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation
WO2004005481A2 (en) * 2002-07-03 2004-01-15 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038143A2 (en) * 2000-11-07 2002-05-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation
WO2004005481A2 (en) * 2002-07-03 2004-01-15 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SALVADOR JESUS M ET AL: "Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases.", NATURE IMMUNOLOGY. APR 2005, vol. 6, no. 4, 27 February 2005 (2005-02-27), pages 390 - 395, XP002349372, ISSN: 1529-2908 *
SALVADOR JESUS M ET AL: "The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway.", NATURE IMMUNOLOGY. APR 2005, vol. 6, no. 4, 27 February 2005 (2005-02-27), pages 396 - 402, XP002349371, ISSN: 1529-2908 *

Also Published As

Publication number Publication date
WO2005077983A2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
WO2006017549A3 (en) Cell-based kinase assay
WO2005034869A3 (en) Compounds and compositions as protein kinase inhibitors
PT1017384E (en) COMPOUNDS BASED ON AZABENZIMIDAZOLE FOR MODULATION OF THE FUNCTION OF A SERINE / TREONINE PROTEIN KINASE
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
MY153898A (en) Compounds and methods for kinase modulation, and indications therefor
WO2004062475A3 (en) Fluorescent assays for protein kinases
WO2005112932A3 (en) Raf modulators and methods of use
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
HK1095587A1 (en) Thienopyrazoles
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
ECSP014105A (en) PIRROLO COMPOUNDS [2,3-d] PYRIMIDINE
WO2000042042A3 (en) High affinity inhibitors for target validation and uses thereof
WO2007023111A3 (en) P38 map kinase inhibitors and methods for using the same
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
WO2006024640A3 (en) Triazolophthalazines
WO2011013133A3 (en) Novel biopesticide compositions and method for isolation and characterization of same
SG166771A1 (en) Novel compounds
WO2005123913A3 (en) Reversibly modified thermostable enzyme compositions and methods of making and using the same
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
DK1742950T3 (en) The pyrazolo [4,3-d] pyrimidines
WO2005042712A3 (en) Heterocyclic compounds and methods of making and using thereof
WO2005077983A3 (en) Modulating p38 kinase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase